Analysis of 3-line generalized Feistel networks with double SD-functions

被引:4
|
作者
Bogdanov, Andrey [1 ,2 ]
Shibutani, Kyoji [3 ]
机构
[1] Katholieke Univ Leuven, ESAT, COSIC, B-3001 Louvain, Belgium
[2] IBBT, B-3001 Louvain, Belgium
[3] Sony Corp, Minato Ku, Tokyo 1080075, Japan
关键词
Cryptography; Block ciphers; Generalized Feistel networks; Substitution diffusion networks; Differential and linear cryptanalysis; Efficiency; Impossible differential;
D O I
10.1016/j.ipl.2011.04.002
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Generalized Feistel networks (GFN) are broadly employed in the design of primitives for block ciphers, stream ciphers, and hash functions. Lately, endowing the functions of GFNs with the structure of nonlinear substitution followed by linear diffusion (substitution-diffusion. SD) has received a great deal of attention. In this contribution, we prove tight lower bounds on the number of differentially and linearly active S-boxes for 3-line GFNs with double SD-functions where two SD-structures are applied one after another. We also show 8-round impossible differentials for 3-line GFNs with bijective functions. Moreover, we demonstrate that the proportion of active S-boxes in all S-boxes for such GFNs is by up to 14% higher than that for 4-line GFNs with double SD-functions, when instantiated with MDS matrices. This indicates that, rather surprisingly, the 3-line GFNs can be more efficient in practice than those with 4 lines. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:656 / 660
页数:5
相关论文
共 50 条
  • [41] Efficiency of anlotinib hydrochloride as 3rd line treatment in patients (pts) from a randomized, double-blind, placebo-controlled phase III trial, an exploratory subgroup analysis of ALTER0303 trial for the previous therapy strategy effect
    Wang, Qiming
    Han, Baohui
    Li, Kai
    Zhang, Li
    Shi, Jianhua
    Wang, Zhehai
    Cheng, Ying
    He, Jianxing
    Shi, Yuankai
    Chen, Weiqiang
    Wang, Xiuwen
    Luo, Yi
    Nan, Kejun
    Jin, Faguang
    Li, Baolan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Analysis of overall survival in adenocarcinoma NSCLC patients receiving 2nd line combination treatment with nintedanib (BIBF 1120) + docetaxel in the LUME-Lung 1 trial: A randomized, double-blind, placebo-controlled phase 3 study
    Mellemgaard, A.
    Kaiser, R.
    Douillard, J. Y.
    Orlov, S. V.
    Krzakowski, M. J.
    Von Pawel, J.
    Gottfried, M.
    Barrueco, J. R.
    Hocke, J.
    Reck, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S798 - S798
  • [43] ANALYSIS OF PATIENT-REPORTED OUTCOMES FROM THE LUME-LUNG 1 TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY IN SECOND-LINE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Novello, Silvia
    Mellemgaard, Anders
    Kaiser, Rolf
    Douillard, Jean-Yves
    Orlov, Sergei
    Krzakowski, Maciej
    Von Pawel, Joachim
    Gottfried, Maya
    Bondarenko, Igor
    Liao, Meilin
    Barrueco, Jose
    Gaschler-Markefski, Birgit
    Griebsch, Ingolf
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1207 - S1207
  • [44] QL1203 vs placebo plus mFOLFOX6 as first-line therapy in RAS wild-type, metastatic colorectal cancer (mCRC): Interim analysis (IA) of a multicenter, randomized, double-blinded, parallel, phase 3 trial.
    Guo, Weijian
    Wang, Yusheng
    Yang, Wenhui
    Li, Yunfeng
    Zhang, Yanqiao
    Zhang, Zhongtao
    Xiong, Hailin
    Li, Changzheng
    Wang, Zhiwu
    Fan, Nanfeng
    Yin, Xianli
    Du, Peng
    Luo, Suxia
    Zhang, Jingdong
    Yu, Dajun
    Zheng, Weie
    Kang, Xiaoyan
    Mao, Kaisheng
    Wang, Zhan
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 190 - 190
  • [45] The Novel Highly Potent and Specific Peroxisome Proliferator-Activated Receptor Alpha Agonist K-877 Improved Liver Enzymes and Lipid Profile Without Adversely Affecting Renal Functions; Integrated Analysis of Phase 2 and Phase 2/3 Double Blind Clinical Trials
    Arai, Hidenori
    Ishibashi, Shun
    Yamashita, Shizuya
    Araki, Eiichi
    Yokote, Koutaro
    Kodama, Tatsuhiko
    CIRCULATION, 2013, 128 (22)
  • [46] Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial (vol 395, pg 1835, 2020)
    Gutzmer, R.
    Stroyakovskiy, D.
    Gogas, H.
    Robert, Caroline
    Lewis, Karl
    Protsenko, Svetlana
    Pereira, Rodrigo P.
    Eigentler, Thomas
    Rutkowski, Piotr
    Demidov, Lev
    Manikhas, Georgy Moiseevich
    Yan, Yibing
    Huang, Kuan-Chieh
    Uyei, Anne
    McNally, Virginia
    McArthur, Grant A.
    Ascierto, Paolo A.
    LANCET, 2020, 396 (10249): : 466 - 466
  • [47] REGARD: A phase 3, randomized, double-blind trial of ramucirumab (RAM) and best supportive care (BSC) versus placebo (PL) and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression (PD) on first-line platinum- and/or fluoropyrimidine-containing combination therapy: Age subgroup analysis.
    Fuchs, Charles S.
    Tomasek, Jiri
    Cho, Jae Yong
    Tomasello, Gianluca
    Goswami, Chanchal
    dos Santos, Lucas Vieira
    Aprile, Giuseppe
    Ferry, David
    Melichar, Bohuslav
    Tehfe, Mustapha Ali
    Tehfe, All
    Topuzov, Eldar
    Zalcberg, John Raymond
    Chau, Ian
    Tabernero, Josep
    Hsu, Yanzhi
    Schwartz, Jonathan D.
    Koshiji, Minori
    Safran, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy-An age-group analysis
    Muro, Kei
    Bodoky, Gyorgy
    Cesas, Alvydas
    Chao, Yee
    Clingan, Philip
    Hironaka, Shuichi
    Komatsu, Yoshito
    Kurteva, Galina Petrova
    Lipatov, Oleg N.
    Nishina, Tomohiro
    Oh, Sang Cheul
    Ohtsu, Atsushi
    Shimada, Yasuhiro
    Sugimoto, Naotoshi
    Van Cutsem, Eric
    Carlesi, Roberto
    Chandrawansa, Kumari
    Wilke, Hansjochen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [49] RAINBOW: A global, phase 3, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy: Results of a multiple Cox regression analysis adjusting for prognostic factors.
    Wilke, Hansjochen
    Van Cutsem, Eric
    Oh, Sang Cheul
    Bodoky, Gyorgy
    Shimada, Yasuhiro
    Hironaka, Shuichi
    Sugimoto, Naotoshi
    Lipatov, Oleg N.
    Kim, Tae-You
    Cunningham, David
    Rougier, Philippe
    Emig, Michael
    Carlesi, Roberto
    Chandrawansa, Kumari
    Muro, Kei
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] RAINBOW: A GLOBAL, PHASE 3, DOUBLE-BLIND STUDY OF RAMUCIRUMAB (RAM) PLUS PACLITAXEL (PTX) VERSUS PLACEBO (PL) plus PTX IN THE TREATMENT OF ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA FOLLOWING DISEASE PROGRESSION ON FIRST-LINE PLATINUM- AND FLUOROPYRIMIDINE-CONTAINING COMBINATION THERAPY: A SUBGROUP ANALYSIS OF WESTERN POPULATION
    Wilke, Hansjochen
    Clingan, Philip
    Ananda, Sumi
    Kurteva, Galina
    Suuroja, Tiit
    Folprecht, Gunnar
    Beny, Alexander
    Pastorelli, Davide
    Cesas, Alvydas
    Nowecki, Zbigniew
    Toganel, Cornelia
    Bodoky, Gyoergy
    Lipatov, Oleg
    Miron, Maria Limon
    Cunningham, David
    Cummins, Sebastian
    Wainberg, Zev
    Ko, Andrew
    Emig, Michael
    Chandrawansa, Kumari
    van Cutsem, Eric
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 171 - 171